| EyeConic: Qualification for Cone-Optogenetics ClinicalTrials.gov ID: NCT05294978 | Tübingen |
| Cell-specific transcorneal electrostimulation (TES) as rehabilitation and support tool for gene therapy in retinitis pigmentosa | Tübingen |
| Rate of Progression in EYS Related Retinal Degeneration | Tübingen |
| Rate of Progression of PCDH15-Related Retinal Degeneration in Usher | Tübingen |
| Belite Bio = DRAGON = Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects | Tübingen |
| Analyse der klinischen Untersuchungen von Patienten mit Netzhautdystrophien nach Behandlung mit Voretigene neparvovec (LuxturnaTM) | Tübingen |
| Klinische Charakterisierung BEST Erkrankung | Tübingen |
| CNGB1 Retinitis Pigmentosa and Allied Disorders | Tübingen |
| Klinische Charakterisierung CNGA1 Retinitis pigmentosa | Tübingen |
| Observational Study for Patients Treated with voretigene Nepravovec | Tübingen |
| A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate). | Tübingen |
| Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial (Color Bridge – CNGBA3 IIb) | Tübingen |
| Evaluation der Wirksamkeit einer transkornealen Elektrostimulation bei Patienten mit Retinitis Pigmentosa – eine multizentrische, prospektive, randomisierte, kontrollierte und doppel-blinde Studie im Auftrag des Gemeinsamen Bundesausschusses (G-BA) | Tübingen |
| A Prospective, Open-label, Phase 1b, Single-arm, Safety Study of an Intravitreal Application of a Recombinant Adeno-associated Virus Vector Expressing CNGA1 (AAV2.NN-CNGA1) in Patients with Retinitis Pigmentosa Due to CNGA1 Mutations | Tübingen |
| NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa | Tübingen |
| Gyrate Atrophy Ocular and systemic Study (Gyros) | Tübingen |
| Project N: Exploration of new sensitive clinical readouts and biomarkers that can be used as clinical endpoints tailored to monitor treatment effects in PDE6A-, PDE6B- and RHO-linked retinitis pigmentosa: a non-interventional trial | Tübingen |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) | Gießen |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN) | Gießen |
| Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Gießen |
| Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Gießen |
| A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2… | Gießen |
| A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis | Gießen |
| Percieve – Nicht-interventionelle Studie (NIS) zur Beobachtung von Patienten mit RPE65-assoziierter Netzhautdegeneration, die mit dem Medikament LTW888 behandelt wurden. Ziel ist es, die Unbedenklichkeit und den Langzeitverlauf der Behandlung zu untersuchen. | Gießen |
